Research & Literature

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C, Snee M, Ashcroft L, et al.

The Lancet. Oncology 2017; (18(8)):1116-1125 doi:10.1016/S1470-2045(17)30318-2.

Prophylactic Cranial Irradiation Following Surgical Resection of Early-Stage Small-Cell Lung Cancer: A Review of the Literature.

Bloom BC, Augustyn A, Sepesi B, et al.

Frontiers in oncology 2017; (7()):228 doi:10.3389/fonc.2017.00228.

Performance Comparison Between 18F-FDG PET/CT Plus Brain MRI and Conventional Staging Plus Brain MRI in Staging of Small Cell Lung Carcinoma.

Kishida Y, Seki S, Yoshikawa T, et al.

AJR. American journal of roentgenology 2018; (211(1)):185-192 doi:10.2214/AJR.17.18935.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Horn L, Mansfield AS, Szczęsna A, et al.

The New England journal of medicine 2018; (379(23)):2220-2229 doi:10.1056/NEJMoa1809064.

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.

Kalemkerian GP, Loo BW, Akerley W, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(10)):1171-1182.

Prevention of Brain Metastases.

Bovi JA

Frontiers in neurology 2018; (9()):758 doi:10.3389/fneur.2018.00758.

A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.

Stinchcombe TE, Fan W, Schild SE, et al.

Cancer 2019; (125(3)):382-390 doi:10.1002/cncr.31813.

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, et al.

Nature reviews. Cancer 2019; (19(5)):289-297 doi:10.1038/s41568-019-0133-9.

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin M, Chan JM, Tenet M, et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019; (14(10)):1784-1793 doi:10.1016/j.jtho.2019.06.002.

Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.

Arbour KC, Riely GJ

JAMA 2019; (322(8)):764-774 doi:10.1001/jama.2019.11058.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Leonetti A, Sharma S, Minari R, et al.

British journal of cancer 2019; (121(9)):725-737 doi:10.1038/s41416-019-0573-8.

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Paz-Ares L, Dvorkin M, Chen Y, et al.

Lancet (London, England) 2019; (394(10212)):1929-1939 doi:10.1016/S0140-6736(19)32222-6.

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.

Schneider BJ, Ismaila N, Aerts J, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(7)):753-766 doi:10.1200/JCO.19.02748.

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.

Schoenfeld AJ, Chan JM, Kubota D, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(11)):2654-2663 doi:10.1158/1078-0432.CCR-19-3563.

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.

Hakozaki T, Kitazono M, Takamori M, Kiriu T

Internal medicine (Tokyo, Japan) 2020; (59(10)):1291-1294 doi:10.2169/internalmedicine.3542-19.

Impact of 18F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Martucci F, Pascale M, Valli MC, et al.

Frontiers in medicine 2019; (6()):336 doi:10.3389/fmed.2019.00336.

Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.

Simone CB, Bogart JA, Cabrera AR, et al.

Practical radiation oncology 2020; (10(3)):158-173 doi:10.1016/j.prro.2020.02.009.

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

Trigo J, Subbiah V, Besse B, et al.

The Lancet. Oncology 2020; (21(5)):645-654 doi:10.1016/S1470-2045(20)30068-1.

Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation.

Pezzi TA, Fang P, Gjyshi O, et al.

JAMA network open 2020; (3(4)):e201929 doi:10.1001/jamanetworkopen.2020.1929.

Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.

Melosky B, Cheema PK, Brade A, et al.

The oncologist 2020; (25(11)):981-992 doi:10.1634/theoncologist.2020-0193.

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.

Giffin MJ, Cooke K, Lobenhofer EK, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(5)):1526-1537 doi:10.1158/1078-0432.CCR-20-2845.

p53 and RB1 regulate Hedgehog responsiveness via autophagy-mediated ciliogenesis.

Cain JE, Watkins DN

Molecular & cellular oncology 2020; (7(6)):1805095 doi:10.1080/23723556.2020.1805095.

Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer.

Chen C, Yang H, Cai D, et al.

Translational lung cancer research 2021; (10(2)):866-877 doi:10.21037/tlcr-20-997.

New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?

Zhang B, Birer SR, Dvorkin M, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2021; (41()):1-10 doi:10.1200/EDBK_320673.

Role of surgery in a case-control study of patients with clinical stage IIIA small cell lung cancer.

Li S, Jin K, Pan Y, et al.

Journal of thoracic disease 2021; (13(5)):2738-2745 doi:10.21037/jtd-20-3047.

Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.

Rajput PS, Khan SR, Singh P, Chawla PA

Anti-cancer agents in medicinal chemistry 2022; (22(5)):812-820 doi:10.2174/1871520621666210706150057.

Molecular Pathology of Lung Cancer.

J Saller J, Boyle TA

Cold Spring Harbor perspectives in medicine 2022; (12(3)) doi:10.1101/cshperspect.a037812.

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Ganti AKP, Loo BW, Bassetti M, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(12)):1441-1464.

NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment.

Koba H, Kimura H, Yoneda T, et al.

Translational lung cancer research 2021; (10(11)):4161-4173 doi:10.21037/tlcr-21-536.

Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?

Kawai H, Matsuoka R, Ito T, Matsubara D

Frontiers in bioscience (Landmark edition) 2022; (27(3)):108 doi:10.31083/j.fbl2703108.

Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.

Megyesfalvi Z, Barany N, Lantos A, et al.

The Journal of pathology 2022; (257(5)):674-686 doi:10.1002/path.5922.

SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection.

Wang Q, Gümüş ZH, Colarossi C, et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023; (18(1)):31-46 doi:10.1016/j.jtho.2022.10.002.

Extensive-stage small-cell lung cancer: Current management and future directions.

Yu Y, Chen K, Fan Y

International journal of cancer 2023; (152(11)):2243-2256 doi:10.1002/ijc.34346.

Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.

Sama S, Kerrigan K, Sinnott JA, et al.

Cancer treatment and research communications 2023; (35()):100686 doi:10.1016/j.ctarc.2023.100686.

Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.

Sun A, Abdulkarim B, Blais N, et al.

Lung cancer (Amsterdam, Netherlands) 2023; (179()):107166 doi:10.1016/j.lungcan.2023.03.002.

A Comparative Analysis of the Predictors, Extent and Impacts of Self-stigma in Patients with Psoriasis and Atopic Dermatitis.

Schlachter S, Sommer R, Augustin M, et al.

Acta dermato-venereologica 2023; (103()):adv3962 doi:10.2340/actadv.v103.3962.

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.

Zheng J, Deng Y, Huang B, Chen X

Frontiers in medicine 2023; (10()):1198950 doi:10.3389/fmed.2023.1198950.

Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting.

Sands J, Subramanian J

Frontiers in oncology 2023; (13()):1161931 doi:10.3389/fonc.2023.1161931.

Influence of initial check, information exchange, final accuracy check, reaction information nursing on the psychology of elderly with lung cancer.

Jiang C, Ma J, He W, Zhang HY

World journal of clinical cases 2024; (12(4)):737-745 doi:10.12998/wjcc.v12.i4.737.

Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial.

Walls GM, Mistry H, Barlesi F, et al.

International journal of radiation oncology, biology, physics 2024; (119(5)):1386-1390 doi:10.1016/j.ijrobp.2024.02.063.

Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a multicenter prospective randomized study.

Chen M, Li R, Kong Y, et al.

BMC cancer 2024; (24(1)):429 doi:10.1186/s12885-024-12123-x.

The relationship between self-stigma and quality of life in long-term hospitalized patients with schizophrenia: a cross-sectional study.

Liu F, Deng H, Hu N, et al.

Frontiers in psychiatry 2024; (15()):1366030 doi:10.3389/fpsyt.2024.1366030.

ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review.

Xu G, Zhou L

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2024; (49(4)):628-636 doi:10.11817/j.issn.1672-7347.2024.230506.

Effects of brain radiotherapy strategies on survival in the era of MRI for patients with limited stage small cell lung cancer.

Yao N, Qin Z, Chen M, et al.

BMC cancer 2024; (24(1)):953 doi:10.1186/s12885-024-12739-z.

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.

Cheng Y, Spigel DR, Cho BC, et al.

The New England journal of medicine 2024; (391(14)):1313-1327 doi:10.1056/NEJMoa2404873.

Association of Serum Biomarkers With Neurocognitive Decline After PCI in Small Cell Lung Cancer: An Exploratory Study of the Phase III NCT01780675 Trial.

Zeng H, Hendriks LEL, Belderbos J, et al.

Clinical lung cancer 2024; (25(7)):653-659.e1 doi:10.1016/j.cllc.2024.08.008.

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.

Reck M, Dziadziuszko R, Sugawara S, et al.

Lung cancer (Amsterdam, Netherlands) 2024; (196()):107924 doi:10.1016/j.lungcan.2024.107924.

Prevalence and Risk Factors of Psychological Distress in Patients With Early-Stage Lung Cancer During Preoperative Period: A Cross-Sectional Study.

Lu L, Zhang B, Li W, et al.

Journal of clinical nursing 2025; (34(8)):3196-3205 doi:10.1111/jocn.17501.

Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis.

Tang J, Wang T, Wu H, et al.

BMC cancer 2024; (24(1)):1351 doi:10.1186/s12885-024-13104-w.

Small cell lung cancer and neuroendocrine tumours.

Pandjarova I, Mercieca D, Gijtenbeek RGP, et al.

Breathe (Sheffield, England) 2024; (20(3)):240004 doi:10.1183/20734735.0004-2024.

Survivorship care plans and adherence to breast and cervical cancer screening guidelines among cancer survivors in a national sample.

Santos-Teles M, Modugu G, Silva IC, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(12)):798 doi:10.1007/s00520-024-08986-2.

A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy.

Kobayashi N, Sunaga N, Yatomi M, et al.

Thoracic cancer 2025; (16(2)):e15512 doi:10.1111/1759-7714.15512.

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.

Sands JM, Champiat S, Hummel HD, et al.

Cancer 2025; (131(3)):e35738 doi:10.1002/cncr.35738.

FDG PET/CT for Staging Lung Carcinoma: An Update.

Sathekge C, Maes J, Maes A, Van de Wiele C

Seminars in nuclear medicine 2025; (55(2)):167-174 doi:10.1053/j.semnuclmed.2025.01.002.

[New perspectives in the management of small cell bronchial cancer].

Berton E, Ardin C, Berardi G, et al.

Bulletin du cancer 2025; (112(3S1)):3S100-3S106 doi:10.1016/S0007-4551(25)00163-8.

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

Chiang AC, Olmedo Garcia ME, Carlisle JW, et al.

ESMO open 2025; (10(4)):104538 doi:10.1016/j.esmoop.2025.104538.

Recent Research on Role of p53 Family in Small-Cell Lung Cancer.

Jeong M, Kim KB

Cancers 2025; (17(7)) doi:10.3390/cancers17071110.

Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases.

Bolte FJ, Dougherty SC, Danos AO, et al.

Clinical lung cancer 2025; (26(5)):347-353.e1 doi:10.1016/j.cllc.2025.03.006.

Primary de novo Epidermal Growth Factor Receptor Mutant Small Cell Lung Carcinomas: Clinicopathological Study of a Rare Entity Presenting in Treatment-Naïve Setting with Review of Literature.

Nambirajan A, Rathor A, Baskarane H, et al.

International journal of surgical pathology 2025; (33(7)):1593-1604 doi:10.1177/10668969251331591.

Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies.

Aijaz A, Pannu S, Abushukair H, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e472794 doi:10.1200/EDBK-25-472794.

Network analysis of core symptom changes in lung cancer survivors: a longitudinal study.

Zhang J, Zhao X, Zhang G, et al.

Journal of cancer survivorship : research and practice 2025; doi:10.1007/s11764-025-01844-y.

Survivorship Challenges and Supportive Care in Lung Cancer.

Ha DM, Jacob RA, Bade BC

Seminars in respiratory and critical care medicine 2025; (46(5)):436-451 doi:10.1055/a-2649-9311.

Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches.

Liu S, Xu T, Cao X, et al.

Biochimica et biophysica acta. Reviews on cancer 2025; (1880(5)):189413 doi:10.1016/j.bbcan.2025.189413.

Psychological Distress in Surgical Lung Cancer Patients: Trajectories, Influencing Factors and Impacts on Quality of Life.

Li J, Yin C, Ye M, et al.

Journal of clinical nursing 2026; (35(1)):289-304 doi:10.1111/jocn.17841.

Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities.

Catania C, Cascetta P, Russo A, et al.

Current oncology (Toronto, Ont.) 2025; (32(10)) doi:10.3390/curroncol32100536.

Prevalence of Histological Transformation in First-Line Osimertinib Non-Small Cell Lung Cancers: Case Series and Literature Review.

Sparavelli R, Bruno R, Celi A, et al.

International journal of molecular sciences 2025; (26(21)) doi:10.3390/ijms262110462.

Comorbidity Network of Self-Stigma, Insomnia, and Mental Health in Chronic Disease Patients: A Network Analysis.

Zhang X, Lin R, Zhang Z, et al.

Psychology research and behavior management 2025; (18()):2333-2345 doi:10.2147/PRBM.S529940.

Tarlatamab for small-cell lung cancer.

Antoniu S, Penisoara T, Rascu S

Expert opinion on biological therapy 2025; (25(12)):1275-1283 doi:10.1080/14712598.2025.2606057.

Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use.

Joshi U, Ong F, Melzer D, et al.

Clinical lung cancer 2026; (27(2)):48-58 doi:10.1016/j.cllc.2025.11.018.

Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database.

Jin X, Zhao W, Li Y, Peng H

Naunyn-Schmiedeberg's archives of pharmacology 2026; (399(7)):10097-10110 doi:10.1007/s00210-026-05028-y.

Prophylactic Cranial Irradiation in Small Cell Lung Cancer: Evolution of Evidence, Current Status, and Future Directions.

Mamidanna S, Bhandari M, Shah C, et al.

Current issues in molecular biology 2025; (47(12)) doi:10.3390/cimb47120998.

Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature.

Güren AK, Demircan NC, Sarı M, Köstek O

Current medical research and opinion 2026; (42(1)):87-97 doi:10.1080/03007995.2026.2629092.